High-Dose Aflibercept Sustains Outcomes Over 96 Weeks

by Medscape • 2023/10/12 • 0 Comments

The recently approved 8-mg dose of aflibercept has shown sustained improvement in vision and anatomical markers out to 96 weeks, according to updated clinical trial results.
Medscape Medical News

Full Story →

← Half a Million Factory Workers in Low-Income Countries Have Vision Screened in Landmark Project Led by Alliance of US Businesses – a Milestone Announced Today, World Sight Day

VIDEO: Glaucoma surgeons face reimbursement issues with MIGS →

Post navigation